Abirtega™ (abiraterone acetate tablets – CivicaScript) — Cigna
Prostate Cancer – Very-High-Risk Group
Initial criteria
- Patient age ≥ 18 years
- Medication is used in combination with prednisone
- According to the prescriber, patient is in the very-high-risk group
- Medication is used in combination with external beam radiation therapy
- Patient meets ONE of the following: (i) Medication is concurrently used with a GnRH analog OR (ii) Patient has had a bilateral orchiectomy
Approval duration
2 years